

SCRAP THE OVERWRAP
FLEXIBLE CONTAINER.
NO EXTRA PACKAGING
REQUIRED.¹⁻⁴



TRUSTED BY HOSPITALS
FOR OVER 19 YEARS^{1-3*}

*FLEXBUMIN 25% Solution was
FDA approved on October 11, 2005.³

INDICATIONS AND LIMITATION OF USE

FLEXBUMIN 5% and 25% are indicated for hypovolemia, hypoalbuminemia (burns), and cardiopulmonary bypass surgery. Albumin is not indicated as an intravenous nutrient.

FLEXBUMIN 25% is also indicated for hypoalbuminemia due to Adult Respiratory Distress Syndrome (ARDS) and nephrosis, and for hemolytic disease of the newborn (HDN).

IMPORTANT SAFETY INFORMATION

Contraindications

- History of hypersensitivity reaction to albumin preparations or to any of the excipients (N-acetyltryptophan and sodium caprylate). Reactions have included anaphylactic shock, anaphylactic reaction, or hypersensitivity/allergic reactions.
- Severe anemia or cardiac failure with normal or increased intravascular volume.

Please see Important Safety Information throughout and click for Full Prescribing Information for **FLEXBUMIN 5%** and **FLEXBUMIN 25%**.

LEADING CONTAINER INNOVATION



50 mL (25% solution)

100 mL (25% solution)

250 mL (5% solution)

FLEXBUMIN is the first human albumin delivered in a flexible, shatterproof container.^{1-4*}

*FLEXBUMIN 25% Solution was FDA approved on October 11, 2005.³

IMPORTANT SAFETY INFORMATION, CONTINUED

Warnings and Precautions

Hypersensitivity Reactions: Have been observed (including anaphylactic reactions). If hypersensitivity reaction is suspected, discontinue administration immediately and implement appropriate standard medical treatment.

Hypervolemia/Hemodilution: Under conditions where hypervolemia and/or hemodilution may occur, adjust the dose and rate of infusion to the patient's volume status. When administering large volumes, monitor hemodynamic parameters. Ensure adequate substitution of other blood constituents and monitor electrolyte balance. Discontinue administration at the first clinical signs of cardiovascular overload.

Hemodynamics: Closely monitor hemodynamic parameters after administration for evidence of cardiac or respiratory failure, renal failure, or increasing intracranial pressure.


Blood Pressure: Monitor blood pressure in trauma patients and postoperative surgery patients in order to detect re-bleeding secondary to clot disruption.

Hemolysis: Do not dilute with Sterile Water for Injection, as there is potential risk of fatal hemolysis and acute renal failure in recipients.

Transmission of Infectious Agents: Because FLEXBUMIN 5% and 25% are made from human plasma, they may carry a risk of transmitting infectious agents (e.g., viruses, other pathogens). No cases of transmission of viral diseases, Creutzfeldt-Jakob disease (CJD) or variant Creutzfeldt-Jakob disease (vCJD) have ever been identified.


Please see Important Safety Information throughout and click for Full Prescribing Information for FLEXBUMIN 5% and FLEXBUMIN 25%.

EFFICIENCY AND EASE OF USE



STERILITY WITHOUT EXTRA STEPS

FLEXBUMIN is designed to maintain sterility during setup and administration—**without a protective overwrap** or requirement to swab the injection port.^{1-3*}



FAST, SIMPLE SETUP

FLEXBUMIN can be set up in **three simple steps**—delivered with no extra packaging and reduced time to administration.^{1,2,5}



REDUCED WASTE

FLEXBUMIN is designed to reduce disposal volume and overall waste—with no protective overwrap needed, and delivered with **no extra packaging**.^{1-4,6}

*Administration caution: Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before the administration of the fluid from the secondary container is complete.^{1,2}

Learn more at [Flexbumin.com](https://www.flexbumin.com).

IMPORTANT SAFETY INFORMATION, CONTINUED

Adverse Reactions

The most serious adverse reactions are hypersensitivity reaction (including anaphylactic reaction) and pulmonary edema.

Please see Important Safety Information throughout and click for Full Prescribing Information for [FLEXBUMIN 5%](#) and [FLEXBUMIN 25%](#).

HOW TO ORDER

FLEXBUMIN [Albumin (Human)] is available in three bag sizes with two concentrations to help meet your center's needs

FLEXBUMIN 25% [ALBUMIN (HUMAN)], USP, 25% SOLUTION

SIZE	EQUIVALENT UNITS (EU)	ORDERING CODE*	NDC NUMBER (BOX/CARTON)	NDC NUMBER (BAG)	PACK FACTOR	INDIVIDUAL BAG DIMENSIONS	BOX DIMENSIONS	SHIPPING WEIGHT
50 mL (12.5 g)	1	2G0201	0944-0493-01	0944-0493-03	24	4" x 6.77" [†]	12" x 6" x 2.5"	4.2 lb
100 mL (25 g)	2	2G0012	0944-0493-02	0944-0493-04	12	4" x 8.748" [†]	12" x 6" x 2.5"	4.2 lb

FLEXBUMIN 5% [ALBUMIN (HUMAN)], USP, 5% SOLUTION

SIZE	EQUIVALENT UNITS (EU)	ORDERING CODE*	NDC NUMBER (BOX/CARTON)	NDC NUMBER (BAG)	PACK FACTOR	INDIVIDUAL BAG DIMENSIONS	BOX DIMENSIONS	SHIPPING WEIGHT
250 mL (12.5 g)	1	2G0250	0944-0495-05	0944-0495-06	10	5.50" x 9.75" [†]	12" x 6" x 2.5"	7 lb

FLEXBUMIN 5% [ALBUMIN (HUMAN)] SOLUTION WITH Y-CONNECTOR SET

SIZE	EQUIVALENT UNITS (EU)	ORDERING CODE*	NDC NUMBER (BOX/CARTON)	NDC NUMBER (BAG)	PACK FACTOR	INDIVIDUAL BAG DIMENSIONS	BOX DIMENSIONS	SHIPPING WEIGHT
250 mL (12.5 g)	1	2G025YC [‡]	0944-0495-05	0944-0495-06	10	5.50" x 9.75" [†]	12" x 6" x 2.5"	7 lb

*Product ordering code to be used only when ordering directly from Takeda.

[†]Includes the port length which is approximately 1.75".

[‡]Use this code to receive Y-connector sets at no charge with your order. You will receive 5 Y-connector sets per case (10 bags/case). Only available from Takeda.

IMPORTANT SAFETY INFORMATION, CONTINUED

Administration Caution

Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before the administration of the fluid from the secondary container is complete.

Please see Important Safety Information throughout and click for [Full Prescribing Information for FLEXBUMIN 5% and FLEXBUMIN 25%](#).

References: 1. FLEXBUMIN 25% [Albumin (Human)], USP, 25% Solution. Prescribing information. Takeda Pharmaceuticals U.S.A., Inc.; 2024. 2. FLEXBUMIN 5% [Albumin (Human)], USP, 5% Solution. Prescribing information. Takeda Pharmaceuticals U.S.A., Inc.; 2024. 3. Data on file. VV-MED-7455—FLEX-013 FLEXBUMIN biologics license application. 4. Data on file. FLEXBUMIN 25% biological license application. 5. Data on file. VV-MED-7220-FLEX-006 Plastic vs glass weights and dimensions. 6. Data on file. No 68128FR. GALAXY 250 mL weight comparisons.